Serum Ficolin-2 Concentrations Are Significantly Changed in Patients with Hepatitis B Virus Infection and Liver Diseases

Overview

Journal Virol Sin

Specialty Microbiology

Date 2015 Jul 30

PMID 26220728

Citations 9

Authors

Tielong Chen

Yilan Hu

Quanquan Ding

Jing Yu

Fubing Wang

FengLing Luo

Xiao-Lian Zhang

Affiliations

Soon will be listed here.

Abstract

Human ficolin-2 is an important lectin complement pathway activator that is secreted from liver cells and has been implicated as an anti-infection innate immune molecule. However, the role of ficolin-2 protein and its dynamic changes over the course of and in the prognosis of chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC) remain unclear. In this study, we analyzed ficolin-2 protein expression in a cohort of individuals with CHB infection, HCC and cirrhosis. A sandwich enzyme-linked immunosorbent assay (ELISA) method was used to measure serum ficolin-2 concentrations. Ficolin-2 expression in liver tissues was detected by immunohistochemical staining. Serum ficolin-2 concentrations in CHB patients were significantly higher than in healthy controls and HBV carriers. After 48 weeks of routine amelioration liver function treatment, serum ficolin-2 concentrations decreased and were positively correlated with favorable alanine aminotransferase (ALT), HBV DNA and HBeAg-seroconversion outcomes. Interestingly, we observed much lower expression of serum and intrahepatic ficolin-2 in HCC and cirrhosis compared with healthy controls. Our findings suggest that serum and intrahepatic ficolin-2 levels may be considered one of the indicators for the response of chronic HBV infection, HCC and cirrhosis.

Citing Articles

Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity.

Zheng P, Dou Y, Wang Q Front Cell Infect Microbiol. 2023; 13:1206720.

PMID: 37424786 PMC: 10324618. DOI: 10.3389/fcimb.2023.1206720.

Components of the Lectin Pathway of Complement in Solid Tumour Cancers.

Cedzynski M, Swierzko A Cancers (Basel). 2022; 14(6).

PMID: 35326694 PMC: 8946279. DOI: 10.3390/cancers14061543.

Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.

Giraudi P, Salvoza N, Bonazza D, Saitta C, Lombardo D, Casagranda B Int J Mol Sci. 2022; 23(5).

PMID: 35269955 PMC: 8911336. DOI: 10.3390/ijms23052813.

The Role of Glycosylation in Infectious Diseases.

Zhang X, Qu H Adv Exp Med Biol. 2021; 1325:219-237.

PMID: 34495538 DOI: 10.1007/978-3-030-70115-4_11.

Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors.

Boldt A, Oliveira-Tore C, Kretzschmar G, Weinschutz Mendes H, Stinghen S, Andrade F Front Immunol. 2021; 11:574457.

PMID: 33643280 PMC: 7904891. DOI: 10.3389/fimmu.2020.574457.

References

Liu J, Ali M, Shi Y, Zhao Y, Luo F, Yu J . Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol. 2009; 6(4):235-44. PMC: 4002714. DOI: 10.1038/cmi.2009.32. View

Hoang T, Toan N, Song L, Ouf E, Bock C, Kremsner P . Ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients. PLoS One. 2011; 6(11):e28113. PMC: 3222672. DOI: 10.1371/journal.pone.0028113. View

Li J, Wu W, Peng G, Chen F, Bai M, Zheng M . HBcAg induces interleukin-10 production, inhibiting HBcAg-specific Th17 responses in chronic hepatitis B patients. Immunol Cell Biol. 2010; 88(8):834-41. DOI: 10.1038/icb.2010.63. View

Honore C, Rorvig S, Hummelshoj T, Skjoedt M, Borregaard N, Garred P . Tethering of Ficolin-1 to cell surfaces through recognition of sialic acid by the fibrinogen-like domain. J Leukoc Biol. 2010; 88(1):145-58. DOI: 10.1189/jlb.1209802. View

. [Diagnostic and treatment guidelines for liver failure]. Zhonghua Gan Zang Bing Za Zhi. 2006; 14(9):643-6. View

El-Serag H . Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6):1264-1273.e1. PMC: 3338949. DOI: 10.1053/j.gastro.2011.12.061. View

Holmskov U, Thiel S, Jensenius J . Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol. 2003; 21:547-78. DOI: 10.1146/annurev.immunol.21.120601.140954. View

Dunkelberger J, Song W . Complement and its role in innate and adaptive immune responses. Cell Res. 2009; 20(1):34-50. DOI: 10.1038/cr.2009.139. View

Wang H, Xue L, Yan R, Zhou Y, Wang M, Cheng M . Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS One. 2013; 8(11):e80585. PMC: 3832452. DOI: 10.1371/journal.pone.0080585. View

10.

Esmat S, Omran D, Sleem G, Rashed L . Serum mannan-binding lectin in egyptian patients with chronic hepatitis C: its relation to disease progression and response to treatment. Hepat Mon. 2012; 12(4):259-64. PMC: 3360935. DOI: 10.5812/hepatmon.704. View

11.

Hummelshoj T, Munthe-Fog L, Madsen H, Fujita T, Matsushita M, Garred P . Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. Hum Mol Genet. 2005; 14(12):1651-8. DOI: 10.1093/hmg/ddi173. View

12.

Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I . Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol. 2005; 175(5):3150-6. DOI: 10.4049/jimmunol.175.5.3150. View

13.

. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167-85. DOI: 10.1016/j.jhep.2012.02.010. View

14.

Pan Q, Chen H, Wang F, Jeza V, Hou W, Zhao Y . L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun. 2012; 4(3):312-24. PMC: 6741490. DOI: 10.1159/000335670. View

15.

Brown K, Keogh M, Tagiuri N, Grainge M, Presanis J, Ryder S . Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex. Clin Exp Immunol. 2006; 147(1):90-8. PMC: 1810446. DOI: 10.1111/j.1365-2249.2006.03264.x. View

16.

Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H . Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem. 1998; 273(33):20721-7. DOI: 10.1074/jbc.273.33.20721. View

17.

Hu Y, Luo F, Fu J, Chen T, Wu S, Zhou Y . Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients. Scand J Immunol. 2013; 77(2):144-50. DOI: 10.1111/sji.12014. View

18.

Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N . A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J Biol Chem. 1996; 271(5):2448-54. DOI: 10.1074/jbc.271.5.2448. View

19.

Song W, Sarrias M, Lambris J . Complement and innate immunity. Immunopharmacology. 2000; 49(1-2):187-98. DOI: 10.1016/s0162-3109(00)80303-3. View

20.

Eisen D, Minchinton R . Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis. 2003; 37(11):1496-505. DOI: 10.1086/379324. View